Remove 2014 Remove Compounding Remove FDA
article thumbnail

Psychedelic research: evaluating the fast-evolving regulatory roadmap

European Pharmaceutical Review

Although some psychedelics have a long history in traditional medicine, regulatory agencies must evaluate psychedelic compounds the same way they assess any other drug. Psychedelic compounds are assessed by regulators the same way as any other drug. This US pathway offers early-phase benefits, including greater FDA collaboration.

article thumbnail

Company profile: NeoImmuneTech

pharmaphorum

By enabling strong CD8 T-cell infiltration in cold tumor tissues, NT-I7, a compound developed by NeoImmuneTech, is capable of promoting a microenvironment that contributes to clinical efficacy, when combined with a CPI. Dr Se Hwan Yang, PhD, President and Chief Executive Officer, founded NeoImmuneTech in January 2014. Creation: Jan.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA).

article thumbnail

9 foods high in estrogen

The Checkup by Singlecare

Foods high in estrogen Phytoestrogens are estrogen-like plant-based compounds and are the form of dietary estrogen obtained from foods we consume. Food and Drug Administration (FDA). Phytoestrogens in postmenopause: The state of the art from a chemical, pharmacological and regulatory perspective , Current Medicinal Chemistry (2014).

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few? 3 Is two too few?

FDA 103
article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

Some of its FDA-approved competitors include: Patents7 Eli Lilly carries big expectations from Trulicity to boost its revenue. In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026).

article thumbnail

Pharmaceutical industry: 2023 in retrospect

European Pharmaceutical Review

During August 2023 the FDA also updated its guidance for NDSRIs 7 and it was closely aligned (but not identical) to EMA’s evolving guidance. 3 Differences include that potency category 1 in FDA’s CPCA approach is 26.5 FDA has also published the AIs of some 265 NDSRIs. ng/day, compared to EMA which is 18 ng/day. 25 Sun et al.

FDA 111